Cargando…
A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy
AIM: To investigate eosinophilia as a potential on-treatment biomarker for patients receiving cancer immunotherapy. MATERIALS & METHODS: We evaluated the association between eosinophilia and treatment response and toxicity in a retrospective cohort of patients receiving cancer immunotherapy. RES...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Science Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720365/ https://www.ncbi.nlm.nih.gov/pubmed/33312694 http://dx.doi.org/10.2144/fsoa-2020-0070 |
_version_ | 1783619837399924736 |
---|---|
author | Krishnan, Tharani Tomita, Yoko Roberts-Thomson, Rachel |
author_facet | Krishnan, Tharani Tomita, Yoko Roberts-Thomson, Rachel |
author_sort | Krishnan, Tharani |
collection | PubMed |
description | AIM: To investigate eosinophilia as a potential on-treatment biomarker for patients receiving cancer immunotherapy. MATERIALS & METHODS: We evaluated the association between eosinophilia and treatment response and toxicity in a retrospective cohort of patients receiving cancer immunotherapy. RESULTS: The study involved 146 patients. Eosinophilia developed in 22%. Patients who developed eosinophilia were more likely to achieve disease control (p = 0.009), with every 0.1 × 10(9)/l rise in eosinophil count, while receiving treatment was associated with a 28% relative increased chance achieving disease control. Although there was a trend toward improved survival, there was no significant association between eosinophilia and improved overall survival (p = 0.136). Patients with eosinophilia were more likely to develop toxicity (p = 0.042). CONCLUSION: Eosinophilia is a potentially useful biomarker warranting further prospective clinical investigation. |
format | Online Article Text |
id | pubmed-7720365 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Future Science Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-77203652020-12-11 A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy Krishnan, Tharani Tomita, Yoko Roberts-Thomson, Rachel Future Sci OA Research Article AIM: To investigate eosinophilia as a potential on-treatment biomarker for patients receiving cancer immunotherapy. MATERIALS & METHODS: We evaluated the association between eosinophilia and treatment response and toxicity in a retrospective cohort of patients receiving cancer immunotherapy. RESULTS: The study involved 146 patients. Eosinophilia developed in 22%. Patients who developed eosinophilia were more likely to achieve disease control (p = 0.009), with every 0.1 × 10(9)/l rise in eosinophil count, while receiving treatment was associated with a 28% relative increased chance achieving disease control. Although there was a trend toward improved survival, there was no significant association between eosinophilia and improved overall survival (p = 0.136). Patients with eosinophilia were more likely to develop toxicity (p = 0.042). CONCLUSION: Eosinophilia is a potentially useful biomarker warranting further prospective clinical investigation. Future Science Ltd 2020-08-03 /pmc/articles/PMC7720365/ /pubmed/33312694 http://dx.doi.org/10.2144/fsoa-2020-0070 Text en © 2020 Tharani Krishnan This work is licensed under the Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Research Article Krishnan, Tharani Tomita, Yoko Roberts-Thomson, Rachel A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy |
title | A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy |
title_full | A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy |
title_fullStr | A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy |
title_full_unstemmed | A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy |
title_short | A retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy |
title_sort | retrospective analysis of eosinophilia as a predictive marker of response and toxicity to cancer immunotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720365/ https://www.ncbi.nlm.nih.gov/pubmed/33312694 http://dx.doi.org/10.2144/fsoa-2020-0070 |
work_keys_str_mv | AT krishnantharani aretrospectiveanalysisofeosinophiliaasapredictivemarkerofresponseandtoxicitytocancerimmunotherapy AT tomitayoko aretrospectiveanalysisofeosinophiliaasapredictivemarkerofresponseandtoxicitytocancerimmunotherapy AT robertsthomsonrachel aretrospectiveanalysisofeosinophiliaasapredictivemarkerofresponseandtoxicitytocancerimmunotherapy AT krishnantharani retrospectiveanalysisofeosinophiliaasapredictivemarkerofresponseandtoxicitytocancerimmunotherapy AT tomitayoko retrospectiveanalysisofeosinophiliaasapredictivemarkerofresponseandtoxicitytocancerimmunotherapy AT robertsthomsonrachel retrospectiveanalysisofeosinophiliaasapredictivemarkerofresponseandtoxicitytocancerimmunotherapy |